Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
500 participants
OBSERVATIONAL
2018-06-01
2023-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Immune Assessment of PD-1 Antibody Therapy in Tumor
NCT06693440
A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies
NCT05862259
The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patients
NCT06496009
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
NCT06031597
Checkpoint Inhibitors in Patients With Solid Tumors: a Retrospective Real-world Study
NCT05719324
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
nivolumab
Consecutive patients treated with nivolumab single or combined chemotherapy/targeting therapy.
Chemotherapy
compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
pembrolizumab
Consecutive patients treated with pembrolizumab single or combined chemotherapy/targeting therapy.
Chemotherapy
compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
toripalimab
Consecutive patients treated with toripalimab single or combined chemotherapy/targeting therapy.
Chemotherapy
compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
sintilimab
Consecutive patients treated with sintilimab single or combined chemotherapy/targeting therapy.
Chemotherapy
compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chemotherapy
compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically or cytologically confirmed diagnosis cancer treated with PD-1 agents
* At least one measurable lesion
* Eastern Cooperative Oncology Group (ECOG) Performance Scale 0 or 1 Adequate organ function
Exclusion Criteria
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Affiliated Hospital of Qingdao University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
zhangxiaochun
Director of Cancer Precision Medical Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaochun Zhang, Dr
Role: PRINCIPAL_INVESTIGATOR
The Affiliated Hospital of Qingdao University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ic-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.